SCHEMBL391939

SCHEMBL391939

CS(=O)(=O)c1ccccc1S(N)(=O)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 13/20 0.56
CA1 P00915 10/20 0.56
CA9 Q16790 10/20 0.56
CA12 O43570 6/20 0.56
CA6 P23280 4/20 0.56
CA5A P35218 4/20 0.56
CA4 P22748 3/20 0.56
CA7 P43166 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
CA14 Q9ULX7 2/20 0.56
CYP2C9 P11712 1/20 0.56
LOX P28300 1/20 0.44
CA3 P07451 1/20 0.44
PLA2G7 Q13093 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
LDHA P00338 1/20 0.43
CDK2 P24941 1/20 0.43
NPC1 O15118 1/20 0.41
MTOR P42345 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6754825 0.98 CA2 (0.54) CA2CA1CA9CA12CA6
Hydrochloric Acid SCHEMBL5740459 0.98 CA2 (0.54) CA2CA1CA9CA12CA6
Acetic Acid SCHEMBL6632015 0.89 CA2 (0.50) CA2CA1CA9CA12CA6
SCHEMBL8106699 0.87 LOX (0.47) CA2CA1CA9CA12CA6
SCHEMBL202947 0.87 CA2 (0.70) CA2CA1CA9CA12CA6
SCHEMBL6820364 0.84 CA2 (0.50) CA2CA1CA9CA12CA6
SCHEMBL10749655 0.84 CA2 (0.67) CA2CA1CA9CA12CA6
SCHEMBL10750170 0.84 CA2 (0.67) CA2CA1CA9CA12CA6
SCHEMBL10750176 0.84 CA2 (0.67) CA2CA1CA9CA12CA6
SCHEMBL17843308 0.81 CA2 (0.52) CA2CA1CA9CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102753520-B N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives 约翰斯霍普金斯大学 2016-06-08 CN claimed
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES THE JOHNS HOPKINS UNIVERSITY 2016-02-18 US claimed
CN-105130855-A Bis-Acylated Hydroxylamine Derivatives UNIV JOHNS HOPKINS 2015-12-09 CN claimed
US-20140235636-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES CARDIOXYL PHARMACEUTICALS, INC. (US) 2014-08-21 US claimed
CN-102753519-A Diacylated hydroxylamine derivatives UNIV JOHNS HOPKINS 2012-10-24 CN claimed
CN-102753520-A N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives UNIV JOHNS HOPKINS 2012-10-24 CN claimed
EP-2509941-A2 N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES The Johns Hopkins University (US) 2012-10-17 EP claimed
EP-2056829-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER Exelixis, Inc. (US) 2009-05-13 EP claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
EP-1999121-A1 NOVEL TETRALINS AS 5-HT6 MODULATORS AstraZeneca AB (SE) 2008-12-10 EP claimed
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-21 US claimed
WO-2008021389-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS, INC. (US) 2008-02-21 WO claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
WO-2007108742-A1 NOVEL TETRALINS AS 5-HT6 MODULATORS ASTRAZENECA AB (SE) 2007-09-27 WO claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
EP-1301480-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2003-04-16 EP claimed
WO-2002006223-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-01-24 WO claimed
EP-0132230-B1 PROCESS FOR THE PREPARATION OF SULFONYL UREA CIBA-GEIGY AG (CH) 1988-10-05 EP claimed
EP-0132230-A2 Process for the preparation of sulfonyl urea CIBA-GEIGY AG (CH) 1985-01-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235636-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 CA2 425/4885CA1 1354/4885CA9 505/4885
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 CA2 425/4885CA1 1354/4885CA9 505/4885
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ CA2 413/4885CA1 573/4885CA9 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.